Search ↗
Tools / Calculator · FDA labels; STEP and SURMOUNT trials

Your titration calendar,
from the label.

GLP-1 medications are started low and stepped up every four weeks to limit nausea. This lays out the label schedule against your start date so you know what dose you should be on in any given week. Your prescriber may hold a step longer; the label allows it.

THIS WEEK YOU SHOULD BE ON

—
Label schedule. Your prescriber may hold any step longer.

How it’s calculated

Wegovy (semaglutide): 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly, 4 weeks per step Ozempic (semaglutide): 0.25 → 0.5 → 1.0 → 2.0 mg weekly, 4 weeks per step (0.25 is not a treatment dose) Zepbound (tirzepatide): 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly, 4 weeks per step, stop at the target dose

Assumptions and limits

  • Schedules are the label defaults. Prescribers commonly hold a dose longer for tolerability; they do not escalate faster.
  • Dates assume one injection per week on the same weekday as your start date.
  • This is a calendar, not a prescription. Dose changes are your prescriber’s decision.
Read this first This tool does arithmetic on numbers you enter. It is not a diagnosis, a prescription or a treatment recommendation. Take the result to a licensed clinician.

References

Regulatory and primary sources

  1. DailyMed: Wegovy labeling, dosage and administration ↗
  2. DailyMed: Zepbound labeling, dosage and administration ↗

Published literature

  1. Jastreboff AM, le Roux CW, Stefanski A, et al.. Tirzepatide for Obesity Treatment and Diabetes Prevention.N Engl J Med 2025.PubMed 39536238 · doi:10.1056/NEJMoa2410819
  2. Garvey WT, Frias JP, Jastreboff AM, et al.. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet 2023.PubMed 37385275 · doi:10.1016/S0140-6736(23)01200-X
  3. Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity.N Engl J Med 2021.PubMed 33567185 · doi:10.1056/NEJMoa2032183
  4. Wilding JPH, Batterham RL, Davies M, et al.. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.Diabetes Obes Metab 2022.PubMed 35441470 · doi:10.1111/dom.14725
  5. Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide Once Weekly for the Treatment of Obesity.N Engl J Med 2022.PubMed 35658024 · doi:10.1056/NEJMoa2206038
  6. Garvey WT, Blüher M, Osorto Contreras CK, et al.. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.N Engl J Med 2025.PubMed 40544433 · doi:10.1056/NEJMoa2502081

Literature retrieved from PubMed on October 18, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Related tools.

BMI & GLP-1 eligibilityGLP-1 expected weight lossCalories & macrosAnnual care cost

Read next.

GLP-1 weight loss providers compared Best GLP-1 telehealth providers